Publications by authors named "Dave Lumen"

Claim this Profile
B
Biological evaluation of integrin αβ-targeted Ga-labeled HEVNPs in HCT 116 colorectal tumor-bearing mice.
Elisavet Lambidis, Chun-Chieh Chen, Dave Lumen, Ana Isabel Fraguas Sánchez, Mirkka Sarparanta

Eur J Pharm Sci· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and ex vivo biodistribution of two Ga-labeled tetrazine tracers: Comparison of pharmacokinetics.
Elisavet Lambidis, Dave Lumén, Elina Koskipahta, Surachet Imlimthan, Brianda B Lopez

Nucl Med Biol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pretargeted PET Imaging with a TCO-Conjugated Anti-CD44v6 Chimeric mAb U36 and [Zr]Zr-DFO-PEG-Tz.
Dave Lumen, Danielle Vugts, Marion Chomet, Surachet Imlimthan, Mirkka Sarparanta

Bioconjug Chem· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of silicon nanoparticles produced by centrifuge chemical vapor deposition for applications in therapy and diagnostics.
Dave Lumen, Shiqi Wang, Ermei Mäkilä, Surachet Imlimthan, Mirkka Sarparanta

Eur J Pharm Biopharm· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors.
Victor Cervera-Carrascon, Dafne C A Quixabeira, Riikka Havunen, Joao M Santos, Emma Kutvonen, Dave Lumen

Mol Ther Oncolytics· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Site-Specific In-Radiolabeling of Dual-PEGylated Porous Silicon Nanoparticles and Their In Vivo Evaluation in Murine 4T1 Breast Cancer Model.
Dave Lumen, Simo Näkki, Surachet Imlimthan, Elisavet Lambidis, Mirkka Sarparanta

Pharmaceutics· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus.
Riikka Havunen, João M Santos, Suvi Sorsa, Tommi Rantapero, Dave Lumen

Mol Ther Oncolytics· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma".
Mikko Siurala, Riikka Havunen, Dipongkor Saha, Dave Lumen, Anu J Airaksinen

Mol Ther· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma.
Mikko Siurala, Riikka Havunen, Dipongkor Saha, Dave Lumen, Anu J Airaksinen

Mol Ther· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A New Highly Reactive and Low Lipophilicity Fluorine-18 Labeled Tetrazine Derivative for Pretargeted PET Imaging.
Outi Keinänen, Xiang-Guo Li, Naveen K Chenna, Dave Lumen, Jennifer Ott

ACS Med Chem Lett· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor.
Siri Tähtinen, Susanna Grönberg-Vähä-Koskela, Dave Lumen, Maiju Merisalo-Soikkeli, Mikko Siurala

Cancer Immunol Res· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis